Previous close | 11.00 |
Open | 12.09 |
Bid | 10.10 |
Ask | 15.00 |
Strike | 185.00 |
Expiry date | 2024-11-15 |
Day's range | 12.09 - 12.09 |
Contract range | N/A |
Volume | |
Open interest | 3 |
SAN MATEO, Calif., June 14, 2024--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain in an oral session (Abstract S160). The presentation will feature data from arm D of SEQUOIA evaluating BRUKINSA in combination with venetoclax in treatment-naïve (TN) patients with high-risk chronic
DUBAI, United Arab Emirates, June 13, 2024--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, and NewBridge Pharmaceuticals have jointly decided to conclude their partnership. This strategic decision aligns with BeiGene’s goals to expand its presence and directly manage operations in the MENA region.
Key Insights The projected fair value for BeiGene is US$318 based on 2 Stage Free Cash Flow to Equity Current share...